Virologic features of SARS-CoV-2 infection in children

Lael M. Yonker[1,2,3*], Julie Boucau[4*], James Regan[5], Manish C. Choudhary[3,5], Madeleine D. Burns[1], Nicola Young[1], Eva J. Farkas[1], Jameson Davis[1], Peter P. Moschovis[2,3], T. Bernard Kinane[2,3], Alessio Fasano[1,2,3], Anne M. Neilan[2,3,6], Jonathan Z. Li[3,5*], Amy K. Barczak[3,4,6*]

1. Massachusetts General Hospital, Mucosal Immunology and Biology Research Center, Boston, MA, USA
2. Massachusetts General Hospital, Department of Pediatrics, Boston, MA, USA
3. Harvard Medical School, Boston, MA, USA
4. Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
5. Brigham and Women's Hospital, Department of Medicine, Boston, MA, USA
6. Massachusetts General Hospital, Department of Medicine, Boston, MA, USA

*Authors contributed equally

Correspondence:

Lael Yonker: Massachusetts General Hospital, 55 Fruit St, Jackson 14, Boston, MA 02114. 617-724-2890. Lyonker@mgh.harvard.edu

Keywords: SARS-CoV-2, Pediatric COVID-19, Viral dynamics

Key points:

- Infants, children and adolescents are equally capable of carrying live, replicating SARS-CoV-2 in their nasal secretions.
- Respiratory secretions of infants, children and adolescents with COVID-19 are most infectious before symptoms develop and during the first five days of illness.
- Children can harbor SARS-CoV-2 variants that could have implications for disease severity and vaccine efficacy.

Abstract

Background: Data on viral factors causing pediatric disease and guidance for pediatric-specific considerations have lagged behind adults throughout the COVID-19 pandemic. As COVID-19 infections and deaths increase in the pediatric population, characterization of SARS-CoV-2 viral dynamics in children would enable data-driven public health guidance.

Methods: Nasal swabs collected from children with COVID-19 were analyzed. Viral load was quantified by RT-PCR; viral culture was assessed by direct observation of cytopathic effects and semiquantitative viral titers. Correlations with age or symptom duration were analyzed. SARS-CoV-2 whole genome amplification was compared with contemporaneous Massachusetts sequences to assess for clustering patterns.

Results: Ninety-seven children with COVID-19 (median age 10 years, range 2 weeks-22 years) were included in this study. Age did not impact SARS-CoV-2 viral load in nasal secretions: children of all ages were equally likely to carry live, replicating virus. Children within the first five days of illness had higher viral loads and rates of culture positivity, and viral load in hospitalized children (n=30) did not differ from hospitalized adults (n=21) with similar duration of symptoms. While pediatric SARS-CoV-2 sequences were representative of those in the community, novel variants were identified.

Conclusions: Children can carry high quantities of live, replicating virus, creating a potential reservoir for transmission and evolution of genetic variants. As guidance around social distancing and masking evolves following vaccine uptake in older populations, a clear understanding of SARS-CoV-2 infection dynamics in children is critical for rational development of public health policies and vaccination strategies to mitigate the impact of COVID-19.

Introduction

Since the SARS-CoV-2 virus ignited the COVID-19 global pandemic, the impact of the virus on children and the role that children play in this pandemic has been understudied. Initially, epidemiology reports suggested that children may have been relatively spared from infection, however, as COVID-19 testing became more available, it has been increasingly recognized that children can be infected with SARS-CoV-2 at rates comparable to adults [1, 2]. To date, roughly 4 million children in the Unites States have been reported as testing positive for COVID-19 [3]. Children under 19 years of age now represent the age group with the highest rate of infection in some regions [4]. Most children generally have milder symptoms when infected with SARS-CoV-2 [5], although a small subset of individuals develop severe disease. In the US, over 16,000 children have been hospitalized for acute COVID-19 with over 300 deaths reported [3]. A baseline understanding of infection in children is a necessary prerequisite to understanding the pathogenesis of severe presentations of COVID-19.

At a population perspective, the role that children play in viral transmission remains poorly understood. Epidemiologic studies suggest that children exhibit lower transmission rates than adults [6], however, these findings are potentially confounded by higher rates of asymptomatic or pauci-symptomatic infection in children, increased social isolation by children early in the pandemic, and reduced COVID-19 testing in children. To date, one small study demonstrated that live virus can be cultured from children [7]. However, the types of systematic studies that have informed our understanding of the viral dynamics of SARS-CoV-2 in adult populations [8-10] have not similarly been carried out in children. As vaccination has become available for adults and adolescents many places in the world and our understanding of transmission dynamics have evolved, masking and distancing policies are being relaxed [11]. Policy changes have necessarily been made in the absence of any insight into the role that pediatric disease might play in ongoing transmission. As viral variants that enhance the potential for transmission

or reduce vaccine efficacy emerge [12-14], the importance of identifying potential reservoirs of viral replication and transmission has been brought into particularly sharp relief. Defining the virologic features of SARS-CoV-2 infection in children and the potential for children to transmit virus will facilitate rational public health decision-making for pediatric populations.

In this work, we sought to define fundamental virologic features of SARS-CoV-2 in a pediatric population. We obtained nasal swabs from children presenting to urgent care clinics or the hospital with PCR-confirmed COVID-19 infection. Clinical factors, such as age, COVID-19 risk factors, and disease severity were compared with viral features including SARS-CoV-2 viral load, isolation of replication-competent virus, and whole viral sequencing. Our data indicate that age, from infancy through adulthood, is not a predictor of viral infection dynamics, and that children of all ages can have high SARS-CoV-2 viral loads of replication-competent virus, including variants, displaying comparable dynamics to those seen in adults.

Methods

Sample collection:

Infants, children and adolescents ≤22 years of age presenting to Massachusetts General Hospital urgent care clinics or the hospital with COVID-19 as determined by PCR testing of nasal specimens (4/2020-4/2021) were offered enrollment in the Institutional Review Board-approved MGH Pediatric COVID-19 Biorepository (IRB # 2020P000955). After informed consent, and assent when appropriate, was obtained verbally, a nasopharyngeal, oropharyngeal and/or anterior nares swab was obtained and placed in phosphate buffered saline. The samples were then aliquoted and stored at -80°C. Nasal samples from adults hospitalized with acute COVID-19 (4/2020-8/2020; enrolled in Institutional Review Board-approved MGH COVID-19 Biorepository, IRB # 2020P000804) were used for comparison of viral load.

Clinical data collection:

Demographic and clinical factors were recorded through a combination of manual charts reviews and data extraction from electronic health records (EHR), then collected in a REDCap database [15] through the Partners Electronic Health Record Registry of Pediatric COVID-19 Disease (IRB # 2020P003588). Trained reviewers collected demographics, SARS-CoV-2 risk factors, comorbid conditions, medications, COVID-19 related symptoms, and laboratory tests. Outcome of initial presentation to care, admission status, and complications of COVID-19 disease were also extracted by manual review.

SARS-CoV-2 viral load quantification:

Virions were pelleted from anterior nasal, oropharyngeal, and nasopharyngeal swab fluids by centrifugation at approximately 21,000 x g for 2 hours at 4°C. RNA was extracted using Trizol-LS (Thermofisher) according to the manufacturer's instructions. RNA was then concentrated by isopropanol precipitation and SARS-CoV-2 RNA was quantified using the CDC N1 primers and probe [https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html] as previously described [9].

Viral Culture:

Vero-E6 cells (ATCC) were maintained in D10+ media [Dulbeco's modified Eagle's media (DMEM) (Corning) supplemented with HEPES (Corning), 1X Penicillin/Streptomycin (Corning), 1X Glutamine (Glutamax, ThermoFisher Scientific) and 10% Fetal Bovine serum (FBS) (Sigma)] in a humidified incubator at 37C in 5% CO2. Vero-E6 cells were passaged every 3-4 days, detached using Trypsin-EDTA (Fisher Scientific) and seeded at 150,000 cells per wells in 24w plates for culture experiments and 20,000 cells per well in 96w plates the day before inoculation for median tissue culture infectious dose (TCID50) experiments.

After thawing, each specimen was filtered through a Spin-X 0.45um filter (Corning) at 10,000 x g for 5min. 50uL of the supernatant was then diluted in 450uL of D^+ media [DMEM supplemented with HEPES, 1X Penicillin/Streptomycin and 1X Glutamine]. The viral culture experiments were performed as previously reported [16] with the following modifications: 100uL of the solution was used to inoculate wells in a 24 well plate and 1mL of D_2^+ media [D+ media with 2% FBS] was added to each well after 1h of incubation. The plates were then placed in a 5% CO2 incubator at 37C. For TCID50 measurements conducted in parallel, 25uL of the Spin-X flow-through was used to inoculate Vero-E6 cells in a 96w plate in the presence of 5ug/mL of polybrene (Santa Cruz Biotechnology) using 5-fold dilutions (5^{-1} to 5^{-6}) and 4 repeats for each sample. The plates were centrifuged for 1 hour at 2,000 x g at 37C before being placed in a 5% CO2 incubator at 37C. The SARS-CoV-2 isolate USA-WA1/2020 strain (BEI Resources) was used as a positive control for CPE in both culture and TCID50 experiments.

Viral culture and TCID50 plates were observed at 3- and 6-days post-infection with a light microscope and wells showing CPE were counted. The TCID50 titers were calculated using the Spearman-Karber method. For the culture plates, the supernatant of the wells displaying CPE was harvested 10-14 days post-infection and RNA was isolated using a QIAamp Viral RNA Mini kit (QIAGEN) for confirmation of the viral sequence.

SARS-CoV-2 sequencing:

cDNA synthesis was performed using Superscript IV reverse transcriptase (Invitrogen). Whole viral amplification was performed with the Artic protocol using multiplexed primer pools designed with Primal Scheme generating 400-bp tiling amplicons [17, 18]. PCR products were pooled and Illumina library construction was performed using the Nextera XT Library Prep Kit (Illumina). The comparison dataset included 183 representative contemporaneous SARS-CoV-2 genomes from

Massachusetts present in GISAID to assess for local clustering. Nucleotide sequence alignment was performed with MAFFT (multiple alignment using fast Fourier transform) [19]. Best-fit nucleotide substitution GTR+G+I was used for the datasets using model selection in IQ-Tree followed by maximum likelihood phylogenetic tree construction using IQ-Tree web server with 1000-bootstrap replicates [20].

Analysis:

All statistical analyses were performed using parametric comparisons in GraphPad Prism (Version 9.1.1), including Pearson correlation, ANOVA with multiple comparisons, and unpaired t test.

Results

Clinical cohort

Ninety-seven children diagnosed with COVID-19 with a mean age of 10 years (range 0-22 years) were included in the study (**Table 1**). Twenty-six children (27%) were asymptomatic but presented because of a COVID-19 exposure or were identified on routine screening. There were more boys (59%) than girls (41%) who acquired SARS-CoV-2 infection. One third of the participants were White (31%), 10% African American/Black race, and 4% were Asian; one third (37%) reported their ethnicity as Hispanic. Past medical history in children is reported in **Supplemental Table 1**. The majority of participants did not require hospitalization (68%); seventeen percent required supplemental oxygen and four percent required invasive or non-invasive respiratory support.

Age does not impact SARS-CoV-2 viral load or recovery of replication competent virus

To assess the relationship between age and viral load (RNA copies/ml) at the time of diagnosis, we performed quantitative PCR on respiratory secretions from children newly diagnosed with

COVID-19. The age of each infected child was analyzed to determine whether age impacted viral load: There was no significant correlation of age with viral load (Pearson correlation, P = 0.39) (**Figure 1A**), nor were there significant differences between ages when grouped by school ages: 0-4 years (infant through pre-school), 5-10 years (elementary school), 11-16 years (middle school), 17 and older (high school and higher education) (ANOVA, P = 0.12) (**Figure 1B**). We then compared viral loads from hospitalized children with hospitalized adults (Adult demographics in **Supplemental Table 1**) with comparable duration of symptoms and found no differences between groups (**Figure 1C**). Thus, a child's age did not appear to impact viral load: all children, from 2 weeks through 22 years of age, were capable of carrying a viral load comparable to adults.

As SARS-CoV-2 RNA detection by RT-PCR does not specify whether replication-competent virus is being shed, we next sought to ascertain risk factors for shedding live virus by performing viral culture assays for recoverable SARS-CoV-2 in parallel with viral load testing. From the 97 participants, we collected 113 samples; live virus was cultured from 32 samples coming from 30 participants. Of note, eight of these children with cultured SARS-CoV-2 were asymptomatic. Higher viral load was significantly predictive of shedding of live virus (t test, P < 0.0001) (**Figure 2A**). Consistent with the results for viral load, age was not correlated with viral culture results; virus was recovered from children ages 1 month through 22 years (**Figure 2B**). Semi-quantitative assessment of the amount of virus shed by an individual participant was assessed by median tissue culture infectious dose (TCID50). TCID50 for culture-positive specimens correlated strongly with viral load (Pearson correlation r = 0.68, P < 0.0001) (**Figure 2C**) but did not correlate with age across all pediatric participants (**Figure 2D**) and did not significantly differ when participants were binned by school age group (**Figure 2E**).

Children with COVID-19 are most infectious within first five days of illness

To define the likely period of infectiousness in our pediatric population, we analyzed viral load, culturability, and TCID50 in comparison with duration of symptoms. Consistent with prior reports in adults [8], viral loads in children were the highest earliest in the course of illness and declined over time (Pearson, $r = -0.38$, $P < 0.001$) (**Figure 3A**). Viral load was highest in the first two days after symptom onset, with significant decrease after 5 days of symptoms and further decline after 10 days of symptoms (ANOVA, $P < 0.0001$) (**Figure 3B**). The relationship between viral load and days of symptoms was consistent between pediatric and adult populations with no evidence of more rapid viral clearance in children (**Figure 3C**). Analysis of pediatric viral culture results demonstrated that children tested early after symptom onset were more likely to shed replication competent virus ($P = 0.004$) (**Figure 3D)**. Correspondingly, semi-quantitative assessment of infectious viral shedding in children showed that the TCID50 was higher early after symptom onset and decreased over time (Pearson $r = -0.27$, $P = 0.004$), with only rare positive cultures detected after the first five days of illness (**Figure 3E**). When grouped by days of symptoms, children in days 0-2 of their symptoms had the highest infectivity, while children with greater than six days of illness were less infectious (ANOVA, $P = 0.009$) (**Figure 3F**).

Pediatric SARS-CoV-2 sequences are representative of those found in the community

We successfully performed whole-viral sequencing of 57 respiratory samples from 54 children. Phylogenetic analysis of these pediatric sequences with contemporaneous Massachusetts sequences from GISAID showed that they are representative of the spectrum of sequences found in the community (**Figure 4**). Notable variants identified in the pediatric samples included four B.1.1.7 and three B.1.526.2 variants. To validate our culture results on a subset of culture-positive samples, we sequenced virus isolated from the supernatant from 8 positive samples. Sequences from the supernatant and respiratory specimens were identical in 7 cases and demonstrated only 1 nucleotide change in the last case.

Discussion

As the global COVID-19 pandemic took hold, older adults infected with SARS-CoV-2 frequently suffered severe illness with high rates of hospitalization and increased risk of mortality. Because the majority of children display mild symptoms when infected with SARS-CoV-2, viral dynamics in children has been understudied and there is a misconception that children, especially younger children, are spared from the disease and cannot carry high level viral loads or shed transmissible virus. While it is now clear that children can become infected with SARS-CoV-2 and develop COVID-19, a full understanding of the dynamics of infection in children is needed to inform public health policies specific to the pediatric population. Here, we show that pediatric patients of all ages, from infancy to young adulthood, can carry a high SARS-CoV-2 viral load in their upper airways, particularly early in the course of infection, and an elevated viral load corresponds with high levels of viable, replicating virus. Pediatric sequences were largely reflective of those found in the general community and the presence of novel variants was identified.

Our findings have significant implications for both public health policy and the potential role of universal vaccination of pediatric populations in fully curbing the COVID-19 pandemic. As vaccination has rolled out in adult populations, public health policies are being adjusted to account for changes in risk that result from vaccination. Our results emphasize the importance of considering and clarifying how these policy changes relate to children. As adult populations have been vaccinated, pediatric cases have represented a growing proportion of infections, currently accounting for nearly 25% of all COVID-19 cases in the United States [3]. Our results suggest that the low rates of transmission in settings such as schools and daycares cannot be attributed to low viral loads, low rates of viral shedding, or rapid clearance of virus in younger patient populations. As changes in masking and distancing policies are implemented for adults,

consideration of how and whether policies changes will be applied for children will be critical for ongoing reduction of new COVID-19 cases.

Our results additionally suggest that pediatric populations have the potential to serve as a community reservoir of actively replicating virus, with implications for both new waves of infection and the evolution of viral variants. The duration of natural and vaccine-induced immunity for each vaccine in clinical use are not yet known. If a community reservoir of actively replicating virus is maintained and transmitted within unvaccinated pediatric populations, that population could then serve as a source of new infections as vaccine-induced immunity wanes in vaccinated adult populations. In addition, viral genomic variants were readily identified in the pediatric samples and these variants have the potential to impact viral transmission [21-23], disease severity [24, 25], and vaccine efficacy [26]. Ongoing viral replication within pediatric populations has the potential to serve as a source of existing and new viral variants that interfere with eradication efforts. Ultimately our results underline the importance of defining public health policy with viral dynamics in children in mind and of including pediatric populations in vaccine efforts aimed at eradication.

Acknowledgements:

The viral culture work was performed in the Ragon Institute BSL3 core, which is supported in part by the NIH-funded Harvard University Center for AIDS Research (P30 AI060354). This research was supported by the National Heart, Lung, and Blood Institute (5K08HL143183 to LMY), the Department of Pediatrics at Massachusetts General Hospital *for* Children (to LMY), the Massachusetts Consortium for Pathogen Readiness and a gift from Mark and Lisa Schwartz (to JZL).

1. Mehta NS, Mytton OT, Mullins EWS, et al. SARS-CoV-2 (COVID-19): What Do We Know About Children? A Systematic Review. Clin Infect Dis **2020**; 71(9): 2469-79.
2. Heald-Sargent T, Muller WJ, Zheng X, Rippe J, Patel AB, Kociolek LK. Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19). JAMA Pediatr **2020**; 174(9): 902-3.
3. Schooley R WH, Spritzler J, Lederman M, Havlir D, Kuritzkes D, Battaglia C, Godfrey C, Robertson M, Schock B, and the AIDS Clinical Trials Group. Therapeutic vaccination with a replication defective adenovirus type 5 HIV-1 gag vaccine in a prospective double-blinded, placebo-controlled trial (ACTG 5197). In: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 3-6, 2008.
4. Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 2: genetic factors and implications for antiretroviral therapeutics. Ann Intern Med **2001**; 134(10): 978-96.
5. Yonker LM, Neilan AM, Bartsch Y, et al. Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses. J Pediatr **2020**; 227: 45-52 e5.
6. Soriano-Arandes A, Gatell A, Serrano P, et al. Household SARS-CoV-2 transmission and children: a network prospective study. Clin Infect Dis **2021**.
7. L'Huillier AG, Torriani G, Pigny F, Kaiser L, Eckerle I. Culture-Competent SARS-CoV-2 in Nasopharynx of Symptomatic Neonates, Children, and Adolescents. Emerg Infect Dis **2020**; 26(10): 2494-7.
8. Weiss A, Jellingso M, Sommer MOA. Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: A systematic review and meta-analysis. EBioMedicine **2020**; 58: 102916.
9. Fajnzylber J, Regan J, Coxen K, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun **2020**; 11(1): 5493.
10. Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature **2020**; 581(7809): 465-9.
11. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet **2008**; 372(9653): 1881-93.
12. Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med **2021**.
13. Liu Y, Liu J, Xia H, et al. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. N Engl J Med **2021**.
14. Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med **2021**.
15. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform **2009**; 42(2): 377-81.

16. Choi B, Choudhary MC, Regan J, et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med **2020**; 383(23): 2291-3.
17. Gonzalez-Reiche AS, Hernandez MM, Sullivan MJ, et al. Introductions and early spread of SARS-CoV-2 in the New York City area. Science **2020**; 369(6501): 297-301.
18. Quick J. nCoV-2019 sequencing protocol v1. Available at: https://www.protocols.io/view/ncov-2019-sequencing-protocol-bbmuik6w.
19. Katoh K, Rozewicki J, Yamada KD. MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization. Brief Bioinform **2019**; 20(4): 1160-6.
20. Trifinopoulos J, Nguyen LT, von Haeseler A, Minh BQ. W-IQ-TREE: a fast online phylogenetic tool for maximum likelihood analysis. Nucleic Acids Res **2016**; 44(W1): W232-5.
21. Zhou B, Thao TTN, Hoffmann D, et al. SARS-CoV-2 spike D614G change enhances replication and transmission. Nature **2021**; 592(7852): 122-7.
22. Deng X, Garcia-Knight MA, Khalid MM, et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell **2021**.
23. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science **2021**; 372(6538).
24. Davies NG, Jarvis CI, Group CC-W, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature **2021**; 593(7858): 270-4.
25. Funk T, Pharris A, Spiteri G, et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Euro Surveill **2021**; 26(16).
26. Garcia-Beltran WF, Lam EC, St Denis K, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell **2021**; 184(9): 2372-83 e9.

Table 1: Participant Demographics, past medical history and disease severity of children with COVID-19 (n=97).

	COVID+ children (N=97)
Age, average (max, min)	10 (0,22)
Sex, number (%)	
Male	57 (59)
Female	40 (41)
Race, number (%)	
White	30 (31)
Black	10 (10)
Asian	4 (4)
Other	39 (40)
Ethnicity, number (%)	
Hispanic	36 (37)
COVID-19 Severity	
Hospitalized, number (%)	30 (31)
Supplemental oxygen	17 (18)
Respiratory support	4 (4)
Outpatient, number (%)	66 (68)

Figure 1: SARS-CoV-2 viral load across age groups. **A**. Viral load for each specimen (n=97) was determined by qPCR, plotted against participant age and analyzed by Pearson correlation. **B**. Viral load levels reported by school age group: 0-4 years old (yo)– infant through pre-school (n=24), 5-10yo – elementary school (n=23), 11-16yo – middle school (n=30), 17yo and over – high school and higher education (n=20). Non-significance by ordinary one-way ANOVA. **C**. Viral load from pediatric participants hospitalized with <10 days of symptoms with COVID-19 (n=28) was compared to hospitalized adults with similar duration of symptoms (n=21). Non-significance by t test. Dotted line depicts limit of detection.



Figure 2: SARS-CoV-2 culture results across age groups and viral load. **A-B**. Samples with observable CPE (culture +) (n=29) or without observable CPE (culture -) (n=87) plotted against viral load (**A**) and participant age (**B**) and compared using t test. **C-D.** Semiquantitative viral titer expressed as TCID50/mL for culture positive samples plotted against corresponding viral load (**C**) or participant age (**D**), Pearson correlation analyzed. **E**. Semiquantitative viral titer reported by school age group, analyzed by ordinary one-way ANOVA. **** P < 0.0001



Figure 3: Culture positivity and duration of symptoms. **A**. Viral load for each specimen was determined by qPCR and plotted against the duration of symptoms (in days). **B**. Viral load reported by binned duration of symptoms. (A and B). Dotted lines depict limit of detection. **C**. Viral load of hospitalized adult and pediatric participants, plotted against duration of symptoms **D.** Duration of symptoms for samples with observable CPE (culture +) and without observable CPE (culture -). **E**. Semiquantitative viral titer expressed as TCID50/mL in samples with observable CPE plotted against corresponding duration of symptoms. **F**. Semiquantitative viral titer reported by binned duration of symptoms. Pearson correlation and ordinary one-way ANOVA used for analysis. ** P < 0.01, *** P < 0.001



Figure 4. Phylogenetic analysis of pediatric and community SARS-CoV-2 sequences. Maximum likelihood tree generated from pediatric sequences (red) and 183 contemporaneous Massachusetts sequences from GISAID.



Supplemental Table 1: Past medical history of children infected with SARS-CoV-2.

Past Medical History - Pediatric Patients
Acute recurrent pancreatitis
ADHD
Alopecia
Asthma
Autism
Cardiac conduction disorder
Chronic kidney disease
Coats Plus Syndrome
Crohn's disease
Cystic Fibrosis
Eczema
Epilepsy
G6PD Deficiency
Glutaric acidemia, type 1
Liver transplant
Mitochondrial complex 1 deficiency
Obesity
Obstructive sleep apnea
Prematurity
Sickle cell trait
Speech delay
Subglottic stenosis
Tracheobronchomalacia

Supplemental Table 2: Demographics, past medical history and disease severity of adults with COVID-19 (n=21) included in analysis of SARS-CoV-2 viral load.

	COVID+ adults (n=21)
Age, average (max, min)	59 (26,76)
Sex, number (%)	
Male	8 (38)
Female	13 (62)
Race, number (%)	
White	13 (62)
Black	5 (24)
Asian	0 (0)
Other	3 (14)
Ethnicity, number (%)	
Hispanic	2 (10)
COVID-19 Severity	
Hospitalized, number (%)	21 (100)
Supplemental oxygen	7 (33)
Respiratory support	7 (33)
Outpatient, number (%)	0 (0)